Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

1.66
-0.0400-2.35%
Post-market: 1.750.0899+5.42%19:59 EDT
Volume:337.85K
Turnover:571.86K
Market Cap:104.30M
PE:-1.30
High:1.75
Open:1.72
Low:1.65
Close:1.70
52wk High:5.55
52wk Low:0.9200
Shares:62.83M
Float Shares:41.16M
Volume Ratio:0.79
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2800
EPS(LYR):-1.2813
ROE:-91.43%
ROA:-41.14%
PB:1.95
PE(LYR):-1.30

Loading ...

Pyxis Oncology presents new MICVO preclinical combo data supporting ongoing pembrolizumab trial

Reuters
·
Yesterday

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

GlobeNewswire
·
Yesterday

Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 28

Pyxis Oncology; Director Rachel Humphrey disposes of common shares worth $16,682

Reuters
·
Mar 26

Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 24

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

TIPRANKS
·
Mar 24

Pyxis Oncology price target lowered to $8 from $9 at Stifel

TIPRANKS
·
Mar 24

Pyxis Oncology Q4 EPS $(0.29) Beats $(0.33) Estimate, Sales $11.038M

Benzinga
·
Mar 23

Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million

Reuters
·
Mar 23

BRIEF-Pyxis Oncology FY Net Income USD -79.621 Million

Reuters
·
Mar 23

Pyxis Oncology FY EPS USD -1.28

THOMSON REUTERS
·
Mar 23

Pyxis Oncology Inc - Updated Data From Micvo Phase 1 Monotherapy Study Expected Mid-Year 2026

THOMSON REUTERS
·
Mar 23

Pyxis Oncology Inc - Expects Cash Runway Into Fourth Quarter of 2026

THOMSON REUTERS
·
Mar 23

Pyxis Oncology Inc - Updated Data From Micvo Phase 1/2 Combination Study With Keytruda Expected 2H 2026

THOMSON REUTERS
·
Mar 23

Press Release: Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Dow Jones
·
Mar 23

Pyxis Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
Mar 13

Pyxis Oncology Announces Interim CEO Amid Leadership Transition

TIPRANKS
·
Feb 07

Pyxis Oncology Appoints Thomas Civik as Interim CEO

Reuters
·
Feb 07

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS)

TIPRANKS
·
Feb 04

Pyxis Oncology Names Thomas Civik Interim CEO

Reuters
·
Feb 03